Riskpilot← Back to searchSign inGet full accessAmylonix AB
ABActiveOrg 5591481170Högbergsgatan 39 4 Tr Lgh 1401Research and experimental development on natural sciences and engineering · NACE 7210Est. 20180 employees
Revenue 2024
SEK 0
EBITDA margin
—
-9% vs 2023
Equity ratio
95.3%
Financial strength
Net profit 2024
SEK -1,1M
-7% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -875K | -9% |
| Net profit | SEK -1,1M | -7% |
| Total assets | SEK 3,8M | -23% |
| Equity | SEK 3,6M | -24% |
| Employees | 0 | — |
Legal name
Amylonix AB
Org number
5591481170
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
5 februari 2018
Share capital
SEK 59 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firmanbeträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva läkemedelsutveckling och därmed förenlig verksamhet.
Address
Högbergsgatan 39 4 Tr Lgh 1401
Email
marianne.hansson@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | — | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −152 | −197 | 0 | −802 | −875 |
| Depreciation & amort. | −0 | −0 | — | −270 | −270 |
| EBIT | −152 | −197 | 0 | −1 072 | −1 145 |
| Net financials | — | — | — | — | 3 |
| Profit before tax | −152 | −197 | 0 | −1 072 | −1 142 |
| Tax | −0 | −0 | — | −0 | −0 |
| Net profit | −152 | −197 | — | −1 072 | −1 142 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3 939 | 4 908 | — | 4 901 | 3 782 |
| Equity | 3 904 | 3 958 | — | 4 745 | 3 603 |
| Long-term debt | 0 | 0 | — | 0 | 0 |
| Short-term debt | 34 | 950 | — | 156 | 179 |
| Total debt | 34 | 950 | — | 156 | 179 |
EBITDA margin
-87500000.0%
This company
15.8%
Market median
-553797568% vs market
20202024
Equity ratio
95.3%
This company
38.2%
Market median
+149% vs market
20202024
Return on equity
-31.7%
This company
18.4%
Market median
-272% vs market
20202024
Net profit margin
-114200000.0%
This company
8.1%
Market median
-1409876643% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KM Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Deputy Board Member | 2020 | |
| Former (1) | ||
| Board of Directors | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Amylonix AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karin Marianne Hansson | Chief Executive Officer | 0 companies |
| David Olof Rikard Bejker | Board of Directors | 0 companies |
| Hanna Elin Elisabeth Lindberg | Board of Directors | 0 companies |
| Carl Erik Mathias Uhlén | Board of Directors | 0 companies |
| Bengt Stefan Ståhl | Chairman | 0 companies |
| Sven Fredrik Yngve Frejd | Deputy Board Member | 0 companies |